Mellitus, founded with a mission to revolutionize diabetes detection and monitoring, focuses on developing advanced in vitro diagnostic tests. The company's core innovation is the measurement of Glycated CD59 (GCD59), a biomarker directly linked to diabetes complications. Mellitus aims to enhance the screening, diagnosis, and monitoring of diabetes, including gestational diabetes, through patient-friendly tests that enable timely interventions. Their market focus includes both clinical applications and pharmaceutical development.
Notable affiliates include experts in diabetes research and diagnostics. Mellitus has achieved significant milestones, such as developing a novel test for gestational diabetes that improves maternal and child health outcomes. The company's impact lies in its potential to transform diabetes management by providing more accurate and early detection methods, thereby reducing long-term complications and healthcare costs.
